Family cord blood banking for sickle cell disease: a twenty-year experience in two dedicated public cord blood banks
Hanadi Rafii,
Françoise Bernaudin,
Helene Rouard,
Valérie Vanneaux,
Annalisa Ruggeri,
Marina Cavazzana,
Valerie Gauthereau,
Aurélie Stanislas,
Malika Benkerrou,
Mariane De Montalembert,
Christele Ferry,
Robert Girot,
Cecile Arnaud,
Annie Kamdem,
Joelle Gour,
Claudine Touboul,
Audrey Cras,
Mathieu Kuentz,
Claire Rieux,
Fernanda Volt,
Barbara Cappelli,
Karina T. Maio,
Annalisa Paviglianiti,
Chantal Kenzey,
Jerome Larghero,
Eliane Gluckman
Affiliations
Hanadi Rafii
Eurocord, Paris-Diderot University EA 3518, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Françoise Bernaudin
Department of Pediatrics, Referral Center for Sickle Cell Disease, Centre Hospitalier Intercommunal, Paris XII University, Créteil, France
Helene Rouard
Cell Therapy Facility, EFS Ile de France, Créteil, France
Valérie Vanneaux
Cell Therapy Facility, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Biotherapy Clinical Investigation Center, Paris-Diderot University, Sorbonne Paris Cité, INSERM, F-75010, France
Annalisa Ruggeri
Eurocord, Paris-Diderot University EA 3518, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Marina Cavazzana
Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, France;Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, France;Paris Descartes–Sorbonne Paris Cité University, Imagine Institute, France
Valerie Gauthereau
Fédération Parisienne Pour le Dépistage et la Prévention des Handicaps de l’Enfant (FPDPHE), Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, France
Aurélie Stanislas
Biotherapy Department, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, France;Biotherapy Clinical Investigation Center, Groupe Hospitalier Universitaire Ouest, Assistance Publique-Hôpitaux de Paris, INSERM, France
Malika Benkerrou
Department of Pediatrics, Referral Center for Sickle Cell Disease, Robert Debré Hospital, Assistance Publique-Hôpitaux de Paris, France
Mariane De Montalembert
Department of Pediatrics, Necker Children’s Hospital, Assistance Publique-Hôpitaux de Paris, France
Christele Ferry
Department of Stem Cell Transplantation, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France
Robert Girot
Department of Hemato-Biology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris, France
Cecile Arnaud
Department of Pediatrics, Referral Center for Sickle Cell Disease, Centre Hospitalier Intercommunal, Paris XII University, Créteil, France
Annie Kamdem
Department of Pediatrics, Referral Center for Sickle Cell Disease, Centre Hospitalier Intercommunal, Paris XII University, Créteil, France
Joelle Gour
Department of Gynecology, Centre Hospitalier Intercommunal, Créteil, France
Claudine Touboul
Department of Gynecology, Centre Hospitalier Intercommunal, Créteil, France
Audrey Cras
Cell Therapy Facility, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Biotherapy Clinical Investigation Center, Paris-Diderot University, Sorbonne Paris Cité, INSERM, F-75010, France
Mathieu Kuentz
Department of Hematology, Groupe Hospitalier Universitaire Henri-Mondor, Créteil, France
Claire Rieux
Unité d’Hémovigilance, Groupe Hospitalier Universitaire Henri-Mondor, Créteil, France
Fernanda Volt
Eurocord, Paris-Diderot University EA 3518, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Barbara Cappelli
Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Karina T. Maio
Eurocord, Paris-Diderot University EA 3518, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Annalisa Paviglianiti
Eurocord, Paris-Diderot University EA 3518, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Chantal Kenzey
Eurocord, Paris-Diderot University EA 3518, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Jerome Larghero
Cell Therapy Facility, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Biotherapy Clinical Investigation Center, Paris-Diderot University, Sorbonne Paris Cité, INSERM, F-75010, France
Eliane Gluckman
Eurocord, Paris-Diderot University EA 3518, Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris, France;Monacord, International Observatory for Sickle Cell Disease, Centre Scientifique de Monaco, Monaco
Efforts to implement family cord blood banking have been developed in the past decades for siblings requiring stem cell transplantation for conditions such as sickle cell disease. However, public banks are faced with challenging decisions about the units to be stored, discarded, or used for other endeavors. We report here 20 years of experience in family cord blood banking for sickle cell disease in two dedicated public banks. Participants were pregnant women who had a previous child diagnosed with homozygous sickle cell disease. Participation was voluntary and free of charge. All mothers underwent mandatory serological screening. Cord blood units were collected in different hospitals, but processed and stored in two public banks. A total of 338 units were stored for 302 families. Median recipient age was six years (11 months-15 years). Median collected volume and total nucleated cell count were 91 mL (range 23–230) and 8.6×108 (range 0.7–75×108), respectively. Microbial contamination was observed in 3.5% (n=12), positive hepatitis B serology in 25% (n=84), and homozygous sickle cell disease in 11% (n=37) of the collections. Forty-four units were HLA-identical to the intended recipient, and 28 units were released for transplantation either alone (n=23) or in combination with the bone marrow from the same donor (n=5), reflecting a utilization rate of 8%. Engraftment rate was 96% with 100% survival. Family cord blood banking yields good quality units for sibling transplantation. More comprehensive banking based on close collaboration among banks, clinical and transplant teams is recommended to optimize the use of these units.